21421_Stable Ischemic Heart Disease Management: Challenges and Controversies

Valentin Fuster, MD, PhD (Co-Chair), Peter Stone, MD (Co-Chair) lead discussion of best practices and controversies in SIHD

The evolution of stable ischemic heart disease (SIHD) management has included changes and new information in all aspects of management, including but not limited to diagnosis and assessment of risk, guideline-directed medical therapy (GDMT), cardiometabolic risk factor control, when to revascularize the SIHD patient, and when revascularization is selected, and decision-making regarding percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG). SIHD guidelines indicate that the objectives of treatment are to 1) reduce premature cardiovascular death; 2) prevent complications of SIHD that directly or indirectly impair patients’ functional well-being, including nonfatal acute mycardial infarction (AMI) and heart failure; 3) maintain or restore a level of activity, functional capacity, and quality of life that is satisfactory to the patient; 4) completely, or nearly completely, eliminate ischemic symptoms; and 5) minimize costs of health care, in particular by eliminating avoidable adverse effects of tests and treatments, by preventing hospital admissions, and by eliminating unnecessary tests and treatments. In this program, a faculty of experts–co-chairs Dr. Valentin Fuster and Dr. Peter Stone, Dr. Mikhail Kosiborod, Dr. L. Kristin Newby, and Dr. Duane Pinto–will describe state-of-the-art management with GDMT and revascularization, discuss current controversies, and debate best practice in challenging cases of SIHD patients. 

Login to your Account